Stock Code: 688520 Stock Abbreviation: China Cell Announcement No.: 2022-028
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.
Recently, China Cell Engineering Co., Ltd. (hereinafter referred to as “Shenzhou Cell Engineering”), a subsidiary of Beijing China Cell Biotechnology Group Co., Ltd. “, approved the change application of the “Drug Production License”, after the change, the production scope “preventive biological products” was added, and the production workshop and production line were added; the classification code was increased by Asa. The specific contents of the changed “Drug Production License” are as follows:
1. Main information of drug production license
Company name: Shenzhou Cell Engineering Co., Ltd.
License number: Beijing 20180005
Social credit code: 91110302740070055D
Classification code: As
Registered address: Room 301, Building 5, Yard 31, Kechuang 7th Street, Beijing Economic and Technological Development Zone, Beijing
Legal representative: Xie Liangzhi
Person in charge of the enterprise: Xie Liangzhi
Quality person in charge: Long Yingguo
Production address and production scope: No. 31, Kechuang 7th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing: Biological products for treatment, biological products for prevention***
Valid until: July 15, 2023
2. Impact on the company and risk warning
China Cell Engineering’s “Drug Production License” newly added the production scope of “preventive biological products (recombinant new coronavirus Alpha+Beta variant S-trimeric protein vaccine, recombinant 14-valent human papillomavirus vaccine (6,11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 type) (insect cells))”, new production workshops and production lines include original solution workshop and original solution production line, adjuvant workshop and adjuvant workshop Preparation production line, preparation workshop and preparation production line, packaging workshop and packaging line; the classification code is increased by Asa.
The new production scope of China Cell Engineering’s “Drug Production License” this time indicates that the company has the conditions and qualifications to produce vaccine products, which is conducive to enriching the company’s product layout, optimizing the company’s production capacity, and improving the company’s core competitiveness.
Due to the characteristics of high technology, high risk and high added value in the biopharmaceutical industry, the clinical trial and marketing review and approval cycle of vaccine products is long and has many links, and the results of clinical research and the progress of the market are uncertain; even if the product goes smoothly Once approved for listing, its future production and sales will also be affected by factors such as market environment, industry policies, supply and demand, and the commercialization prospects of the products are also subject to greater uncertainty.
The company will actively promote the relevant R&D projects, and fulfill the obligation of information disclosure on the follow-up progress of the project in strict accordance with the relevant regulations. Investors are advised to make decisions with caution and pay attention to preventing investment risks.
Special announcement.
Board of Directors of Beijing Shenzhou Cell Biotechnology Group Co., Ltd.
June 7, 2022
<!–
–>